DANYELZA® (naxitamab-gqgk)

Intended for US audiences only.

Please see Full Prescribing Information, including Boxed Warning at
 https://labeling.ymabs.com/danyelza

Nobody wants to hear that their child’s high-risk neuroblastoma has 
returned or has been unresponsive to treatment. Fortunately, research
 has led to an additional treatment option called DANYELZA.

This channel has been created to help you learn more about DANYELZA
— the only FDA-approved immunotherapy specifically for children with
 high-risk neuroblastoma who had an incomplete response to induction
 or relapse therapy and who also have disease in the bone and/or 
bone marrow. Incomplete response is defined as stable disease, partial 
response, or minor response to prior therapy.

©2025 Y-mAbs Therapeutics, Inc. All rights reserved.
January 2025 NAX-000673_v1